Artificial intelligence framework for predictive cardiovascular and stroke risk assessment models: A narrative review of integrated approaches using carotid ultrasound.

10-Year risk Artificial intelligence-based risk assessment Atherosclerosis Cardiovascular disease Integrated models Statistical risk calculator Stroke

Journal

Computers in biology and medicine
ISSN: 1879-0534
Titre abrégé: Comput Biol Med
Pays: United States
ID NLM: 1250250

Informations de publication

Date de publication:
11 2020
Historique:
received: 11 08 2020
revised: 10 09 2020
accepted: 04 10 2020
pubmed: 17 10 2020
medline: 22 6 2021
entrez: 16 10 2020
Statut: ppublish

Résumé

Cardiovascular disease (CVD) is the leading cause of mortality and poses challenges for healthcare providers globally. Risk-based approaches for the management of CVD are becoming popular for recommending treatment plans for asymptomatic individuals. Several conventional predictive CVD risk models based do not provide an accurate CVD risk assessment for patients with different baseline risk profiles. Artificial intelligence (AI) algorithms have changed the landscape of CVD risk assessment and demonstrated a better performance when compared against conventional models, mainly due to its ability to handle the input nonlinear variations. Further, it has the flexibility to add risk factors derived from medical imaging modalities that image the morphology of the plaque. The integration of noninvasive carotid ultrasound image-based phenotypes with conventional risk factors in the AI framework has further provided stronger power for CVD risk prediction, so-called "integrated predictive CVD risk models." of the review: The objective of this review is (i) to understand several aspects in the development of predictive CVD risk models, (ii) to explore current conventional predictive risk models and their successes and challenges, and (iii) to refine the search for predictive CVD risk models using noninvasive carotid ultrasound as an exemplar in the artificial intelligence-based framework. Conventional predictive CVD risk models are suboptimal and could be improved. This review examines the potential to include more noninvasive image-based phenotypes in the CVD risk assessment using powerful AI-based strategies.

Identifiants

pubmed: 33065389
pii: S0010-4825(20)30374-7
doi: 10.1016/j.compbiomed.2020.104043
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

104043

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

Ankush D Jamthikar (AD)

Department of Electronics and Communication Engineering, Visvesvaraya National Institute of Technology, Nagpur, Maharashtra, India.

Deep Gupta (D)

Department of Electronics and Communication Engineering, Visvesvaraya National Institute of Technology, Nagpur, Maharashtra, India.

Luca Saba (L)

Department of Radiology, University of Cagliari, Italy.

Narendra N Khanna (NN)

Department of Cardiology, Indraprastha APOLLO Hospitals, New Delhi, India.

Klaudija Viskovic (K)

Department of Radiology and Ultrasound, University Hospital for Infectious Diseases, Croatia.

Sophie Mavrogeni (S)

Cardiology Clinic, Onassis Cardiac Surgery Center, Athens, Greece.

John R Laird (JR)

Heart and Vascular Institute, Adventist Health St. Helena, St Helena, CA, USA.

Naveed Sattar (N)

Institute of Cardiovascular & Medical Sciences, University of Glasgow, Scotland, UK.

Amer M Johri (AM)

Department of Medicine, Division of Cardiology, Queen's University, Kingston, Ontario, Canada.

Gyan Pareek (G)

Minimally Invasive Urology Institute, Brown University, Providence, RI, USA.

Martin Miner (M)

Men's Health Center, Miriam Hospital Providence, Rhode Island, USA.

Petros P Sfikakis (PP)

Rheumatology Unit, National Kapodistrian University of Athens, Greece.

Athanasios Protogerou (A)

Department of Cardiovascular Prevention & Research Unit Clinic & Laboratory of Pathophysiology, National and Kapodistrian Univ. of Athens, Greece.

Vijay Viswanathan (V)

MV Hospital for Diabetes and Professor M Viswanathan Diabetes Research Centre, Chennai, India.

Aditya Sharma (A)

Division of Cardiovascular Medicine, University of Virginia, Charlottesville, VA, USA.

George D Kitas (GD)

R & D Academic Affairs, Dudley Group NHS Foundation Trust, Dudley, United Kingdom.

Andrew Nicolaides (A)

Vascular Screening and Diagnostic Centre and University of Nicosia Medical School, Nicosia, Cyprus.

Raghu Kolluri (R)

OhioHealth Heart and Vascular, Ohio, USA.

Jasjit S Suri (JS)

Stroke Monitoring and Diagnostic Division, AtheroPoint™, Roseville, CA, USA. Electronic address: jasjit.suri@atheropoint.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH